Chemosaturation with percutaneous hepatic perfusion of melphalan for metastatic uveal melanoma



Modi, Sachin, Gibson, Tom, Vigneswaran, Ganesh, Patel, Shian, Wheater, Matthew, Karydis, Ioannis, Gupta, Sanjay, Takhar, Arjun, Pearce, Neil, Ottensmeier, Christian ORCID: 0000-0003-3619-1657
et al (show 1 more authors) (2022) Chemosaturation with percutaneous hepatic perfusion of melphalan for metastatic uveal melanoma. MELANOMA RESEARCH, 32 (2). pp. 103-111.

Access the full-text of this item by clicking on the Open Access link.

Abstract

Uveal melanoma, the most common primary ocular malignancy in adults, carries a poor prognosis: 50% of patients develop the metastatic disease with a 10-25% 1-year survival and no established standard of care treatment. Prior studies of melphalan percutaneous hepatic perfusion (M-PHP) have shown promise in metastatic uveal melanoma (mUM) patients with liver predominant disease but are limited by small sample sizes. We contribute our findings on the safety and efficacy of the procedure in the largest sample population to date. A retrospective analysis of outcome and safety data for all mUM patients receiving M-PHP was performed. Tumour response and treatment toxicity were evaluated using RECIST 1.1 and Common Terminology Criteria for Adverse Events v5.03, respectively. 250 M-PHP procedures were performed in 81 patients (median of three per patient). The analysis demonstrated a hepatic disease control rate of 88.9% (72/81), a hepatic response rate of 66.7% (54/81), and an overall response rate of 60.5% (49/81). After a median follow-up of 12.9 months, median overall progression-free (PFS) and median overall survival (OS) were 8.4 and 14.9 months, respectively. There were no fatal treatment-related adverse events (TRAE). Forty-three grade 3 (29) or 4 (14) TRAE occurred in 23 (27.7%) patients with a significant reduction in such events between procedures performed in 2016-2020 vs. 2012-2016 (0.17 vs. 0.90 per patient, P < 0.001). M-PHP provides excellent response rates and PFS compared with other available treatments, with decreasing side effect profile with experience. Combination therapy with systemic agents may be viable to further advance OS.

Item Type: Article
Uncontrolled Keywords: interventional radiology, melanoma, melphalan, outcome assessment
Divisions: Faculty of Health and Life Sciences
Faculty of Health and Life Sciences > Institute of Systems, Molecular and Integrative Biology
Depositing User: Symplectic Admin
Date Deposited: 23 May 2022 08:59
Last Modified: 18 Jan 2023 21:01
DOI: 10.1097/CMR.0000000000000806
Open Access URL: https://journals.lww.com/melanomaresearch/Fulltext...
Related URLs:
URI: https://livrepository.liverpool.ac.uk/id/eprint/3155331